Sleep-Wake Disorders

Insomnia drug pipeline

  • ICD-11 7A00
  • MeSH D007319

1 compound from 1 company is in active clinical development for insomnia, including 1 at Phase 3 or beyond.

1Compound
1Company
1Phase 3+
50Trials recruiting
  • Approved 1

Mechanisms: Small molecule (1)

Pipeline data compiled July 2026 · every fact sourced.

Upcoming readouts & recent results

  • 2025-08-25ReportedVornorexant (TS-142)Regulatorymet

    Japan MHLW approved Vorzzz (vornorexant hydrate) 2.5/5/10 mg for insomnia.

  • 2025-06-28ReportedVornorexant (TS-142)Full resultsmetNCT05453136

    Pivotal Phase 3 TS142-301 met primary (sSL) and key secondary (sSE) endpoints at both 5 mg and 10 mg (p<0.001).

See the full catalyst calendar →

Compounds in development (1)

CompoundCompanyPhaseStatusMechanism
Vornorexant (TS-142)OOTEMON Co., Ltd.ApprovedApprovedOX2 receptor Antagonist

Trials recruiting now (50)

50 drug-interventional insomnia trials recruiting now, of 427 registered interventional trials. Browse all on ClinicalTrials.gov →

Showing the 12 most advanced of 50 recruiting drug trials · see all on ClinicalTrials.gov →

Frequently asked

How many drugs are in development for insomnia?
1 compound from 1 company is in active clinical development for insomnia, including 1 at Phase 3 or beyond.
Which insomnia drugs are in Phase 3?
Phase 3 (or later) programs for insomnia include Vornorexant (TS-142).
How many clinical trials are recruiting for insomnia?
50 drug-interventional insomnia trials are currently recruiting participants, out of 427 registered interventional trials.